Literature DB >> 10560802

Lactate- or bicarbonate-buffered solutions in continuous extracorporeal renal replacement therapies.

H P Kierdorf1, C Leue, S Arns.   

Abstract

BACKGROUND: Continuous renal replacement therapies (CRRTs) are well accepted for critically ill patients with acute renal failure (ARF). Today, daily fluid exchange in CRRT reaches 30 to 40 liter and more. Therefore, the composition of the substitution/dialysate fluid, often primarily developed either for intermittent treatment or for peritoneal dialysis, becomes more relevant. Lactate (30 to 45 mmol/liter) is frequently used as the buffer because of the high stability of this substance. However, lactate is thought to have negative effects on metabolic and hemodynamic parameters.
METHODS: Published data for different substitution fluids are presented with respect to acidosis and lactate concentration, uremia, and hemodynamic and metabolic alterations.
RESULTS: Only a few studies compare substitution fluids with different buffers. Uremia and acidosis (pH, base excess) were sufficiently controlled during CRRT with an exchange volume of in average 30 liters using either buffer. If patients with severe liver failure and lactic acidosis were excluded, no difference in hemodynamic and metabolic parameters between the solutions occurred. The plasma lactate concentration was elevated during lactate use in some cases, but lactate levels remained within normal limits in patients without liver impairment. The bicarbonate concentration in the solutions should exceed 35 to 40 mmol/liter, as in some cases the buffer capacity of the solutions was inadequate. In patients with severe liver failure or lactic acidosis, solutions with lactate buffer were shown not to be indicated.
CONCLUSION: In patients with reduced lactate metabolism, for example, concomitant severe liver failure, after liver transplantation or in lactic acidosis, bicarbonate-buffered solutions should be used. In nearly all other cases of critically ill patients with ARF, lactate-buffered solutions may be used as well as bicarbonate solutions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10560802

Source DB:  PubMed          Journal:  Kidney Int Suppl        ISSN: 0098-6577            Impact factor:   10.545


  6 in total

1.  Solutions for peritoneal dialysis in children: recommendations by the European Pediatric Dialysis Working Group.

Authors:  Claus Peter Schmitt; Sevcan A Bakkaloglu; Günter Klaus; Cornelis Schröder; Michel Fischbach
Journal:  Pediatr Nephrol       Date:  2011-03-31       Impact factor: 3.714

2.  Crystalloid strong ion difference determines metabolic acid-base change during acute normovolaemic haemodilution.

Authors:  Thomas J Morgan; Balasubramanian Venkatesh; Jonathan Hall
Journal:  Intensive Care Med       Date:  2004-02-28       Impact factor: 17.440

Review 3.  The meaning of acid-base abnormalities in the intensive care unit: part III -- effects of fluid administration.

Authors:  Thomas J Morgan
Journal:  Crit Care       Date:  2004-09-03       Impact factor: 9.097

4.  The Value of Blood Lactate Measurements in ICU: An Evaluation of the Role in the Management of Patients on Haemofiltration.

Authors:  P Holloway; S Benham; A St John
Journal:  EJIFCC       Date:  2000-12-28

5.  Acetate- versus lactate-buffered crystalloid solutions: A systematic review with meta-analysis and trial sequential analysis.

Authors:  Karen Louise Ellekjaer; Anders Perner; Praleene Sivapalan; Morten Hylander Møller
Journal:  Acta Anaesthesiol Scand       Date:  2022-05-10       Impact factor: 2.274

6.  Renal replacement therapy for acute renal failure in children: European guidelines.

Authors:  Vladimirs Strazdins; Alan R Watson; Ben Harvey
Journal:  Pediatr Nephrol       Date:  2003-12-18       Impact factor: 3.714

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.